Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26397089 | 0.92 | EGFR (0.47) | EGFRALKULK1IGF1RPLK1 | |
| SCHEMBL26397198 | 0.90 | EGFR (0.47) | EGFRALKULK1IGF1RPLK1 | |
| SCHEMBL26397273 | 0.87 | EGFR (0.57) | EGFRALKIGF1RPLK1 | |
| SCHEMBL26384074 | 0.82 | EGFR (0.52) | EGFRALKULK1IGF1RPLK1 | |
| SCHEMBL26397384 | 0.82 | EGFR (0.46) | EGFRALK | |
| SCHEMBL26402229 | 0.81 | PLK1 (0.42) | EGFRALKBRD4IGF1RPLK1 | |
| SCHEMBL26384215 | 0.81 | EGFR (0.47) | EGFR | |
| SCHEMBL26395787 | 0.80 | ULK1 (0.64) | EGFRALKULK1IGF1RPLK1 | |
| SCHEMBL26395755 | 0.80 | ALK (0.57) | EGFRALKULK1IGF1RPLK1 | |
| SCHEMBL26379978 | 0.79 | EGFR (0.57) | EGFRALKBRD4ULK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 58/4885BRD4 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.